Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds

Draft Report From Pricing Watchdog Calls Out Wegovy, Saxenda

 
• By Jessica Merrill

Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.

magnified money
A ICER report is taking a closer look at obesity drug prices • Source: Alamy

More from Drug Pricing

More from Scrip